Melanoma TrialFinder

For patients

Find a trial

Search our trial database to find available and relevant melanoma clinical trials for you

Find a trial

19 trials in 63 locations

ATOM: Adjuvant Tebentafusp in High Risk Ocular Melanoma

After removal of a uveal melanoma, observation is currently the standard of care treatment for patients that don’t have metastases.For patients with high-risk primary uveal melanoma about 50% will have a recurrence (the melanoma will come back) following the removal (resection) of the tumour. Therefore, this trial aims to look at whether adjuvant treatment with tebentafusp may lower the chance of the melanoma coming back (recurring) in these high-risk patients.Tebentafusp is a proven and [...]

Locations: Clatterbridge Cancer Centre, Beatson West of Scotland Cancer Centre, Mount Vernon Cancer Centre

PRISM-MEL-301: Brenetafusp (IMC-F106C) Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma

This trial aims to investigate if an experimental treatment called Brenetafusp (IMC-F106C) in combination with standard immunotherapy treatment nivolumab is more effective at treating unresectable, advanced melanoma than current standard treatment of nivolumab alone or relatlimab-nivolumab treatment.The trial also aims to look at how well patients tolerate the new treatment combination, for example, if they experience any side effects.IMC-F106C is an experimental treatment that helps the body’s natural defence (immune system) to find, attack [...]

Locations: Taunton and Somerset NHS Foundation Trust, University Hospitals Bristol and Weston Clinical Trials Unit, Oxford University Hospitals NHS Foundation Trust, The Royal Marsden Hospital (SURREY), The Beatson West of Scotland Cancer Centre, ROYAL FREE HOSPITAL, East and North Hertfordshire NHS Trust, Queen Elizabeth Hospital Birmingham, Sarah Cannon Research Institute, Norfolk and Norwich University Hospital, Addenbrookes Hospital, The Christie NHS Foundation Trust, The Royal Marsden Hospital (LONDON), The Clatterbridge Cancer Centre - Aintree, SOUTHEND HOSPITAL

CARD-IO: CARDiac toxicity following ImmunOtherapy treatment for melanoma

The types of standard immunotherapy treatment used for patients with melanoma are known as immune checkpoint inhibitors (ICI), such as pembrolizumab, nivolumab or ipilimumab. While they work very well to treat melanoma, some patients can experience side effects. These side effects can affect any part of the body and patients can experience them from a mild level up to a very severe level.There has been a lot of research on the side effects that [...]

Locations: ROYAL FREE HOSPITAL, The Royal Marsden Hospital (LONDON)

DyNAMIc: Circulating tumour DNA guided Adaptive BRAF and MEK Inhibitor therapy

Targeted therapy with encorafenib and binimetinib is currently a standard treatment used for patients that have unresectable or metastatic melanoma with a BRAF positive mutation. Targeted treatments are intended to turn off cancer cells with a specific gene mutation and can shrink or slow the growth of cancer cells that have that mutation.Encorafenib and binimetinib are taken as tablets by the patient at home every day (continuously). The treatment can be given as long [...]

Locations: The Royal Marsden Hospital (LONDON), Addenbrookes Hospital, Royal Preston Hospital, Nottingham University Hospitals NHS Trust, POOLE GENERAL HOSPITAL NHS TRUST, Northern Centre for Cancer Care - Freeman Hospital, Guys and St Thomas' NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, Royal United Hospitals Bath, Velindre University NHS Trust, The Royal Marsden Hospital (SUTTON), The Clatterbridge Cancer Centre - LIVERPOOL, University Hospital Southampton, The Christie NHS Foundation Trust

EXCISE: EXamining antibiotics for ulCerated skIn cancer Surgical Excision

This trial aims to investigate if antibiotics can stop infections from developing after surgery for ulcerated skin cancer. Surgery is the first line treatment for most skin cancers. However, surgery can lead to complications such as infection. Some people develop skin cancers that break through the skin surface causing a wound on the skin (called an ulcerated skin cancer) which are more likely to develop a wound infection after surgery. Doctors often give antibiotics [...]

Locations: Norfolk and Norwich University Hospital, Brighton General Hospital, West Suffolk Hospital, Stoke Mandeville Hospital, University Hospital of Wales, Royal United Hospitals Bath, Churchill Hospital, Northampton General Hospital, Morriston Hospital, SBUHB, Walsall Manor Hospital, Victoria Hospital, NHS Fife, The James Cook University Hospital, Castle Hill Hospital

USZ-STRIKE: Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

The trial aims to investigate how effective it is to give standard immunotherapy treatment in combination with stereotactic radiosurgery, compared to giving standard immunotherapy treatment alone, to treat stage 4 melanoma patients whose melanoma has spread to the brain (also known as brain metastases).It is not currently known when the best time is to give stereotactic radiosurgery for it to be most effective at treating the brain metastases. Therefore, doctors want to look at [...]

Locations: The Christie NHS Foundation Trust

MISST: Melanoma Immunomodulation and Immune Responses of the Skin Study: A Translational Science Research Protocol

This study aims to better understand how genes as well as the immune system affect the development of melanoma. Researchers hope that the results could improve how melanoma is detected and also lead to the development of new treatments for melanoma.The early stages of melanoma can be treated effectively by using surgery to remove the melanoma, but no cure is available at the moment in more advanced melanoma. Doctors currently don’t know what causes [...]

Locations: Guy's and St Thomas' NHS Trust

MITRE: Microbiome Immunotherapy Toxicity and Response Evaluation

The MITRE study aims to investigate whether there is a gut microbiome ‘signature’ (pattern) which can predict which patients receiving immune checkpoint inhibitors are likely to respond to treatment.The study also aims find out whether there is a link between the gut microbiome and risk of severe side effects associated with immune checkpoint inhibitor treatment. Gut Microbiome: People have hundreds of thousands of different types of natural bacteria living in the gastrointestinal tract, which [...]

Locations: Sherwood Forest Hospitals NHS Foundation Trust, Royal United Hospital Bath, Royal Cornwall Hospital, Bristol Haematology and Oncology Centre, Somerset NHS Foundation Trust, Royal Surrey County Hospital, Poole Hospital, Singleton Hospital, Nottingham University Hospitals NHS Trust, The Christie NHS Foundation Trust, Weston Park Hospital (Sheffield), Addenbrookes Hospital (Cambridge), Velindre Cancer Centre (Cardiff), Royal Devon and Exeter Hospital, The Queen Elizabeth Hospital King's Lynn, Western General Hospital (Edinburgh), , Royal Bournemouth Hospital, University Hospital Southampton

MANIFEST: Multiomic ANalysis of Immunotherapy Features Evidencing Success and Toxicity

MANIFEST is a UK‑wide observational study aiming to understand why some people benefit from immunotherapy while others do not, and why some develop immune‑related side effects.It aims to investigate:How patients respond to immunotherapy over timeBiological signs (biomarkers) linked to response, resistance, or side effectsIt also aims to look at:Immune system activity in the bloodTumour samples and genetic information (where available)Stool and other samples to understand the microbiomeHow clinical features and biology interact to influence [...]

Locations: The Christie NHS Foundation Trust

IDE196-009: Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

The trial aims to investigate the effects of giving neoadjuvant therapy with IDE196 to patients planned to have surgery to remove the eyeball (enucleation), or plaque brachytherapy (a type of radiotherapy) to treat their melanoma tumour. The idea of giving neoadjuvant therapy is to give it before the main treatment to reduce the size of the melanoma so that the treatment given afterwards may be easier, or more effective, at removing the melanoma. In [...]

Locations: University College London Hospitals NHS Foundation Trust, The Clatterbridge Cancer Centre - LIVERPOOL

PerceIVe: Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage 4 Melanoma

Immunotherapy treatment has changed the outlook for patients with advanced melanoma in the last 10 years.Patients who have a complete response (no remaining signs of melanoma in the body) to immunotherapy treatment have follow-up scans to check that their melanoma hasn’t returned. They have imaging scans (including CT scan, MRI and/or PET scan) every 3-6 months for 5-10 years (or longer) after stopping treatment, even though researchers now know that they have a low [...]

Locations: Cambridge University Hospitals NHS Trust, Velindre Cancer Centre, ROYAL FREE HOSPITAL, ST HELEN'S & KNOWSLEY HOSPITALS TRUST, The Beatson West of Scotland Cancer Centre, Weston Park Hospital, East and North Hertfordshire NHS Trust, The Christie NHS Foundation Trust, Musgrove Park Hospital, University Hospital Southampton, The Clatterbridge Cancer Centre - LIVERPOOL, University Hospital Birmingham, Leicester Royal Infirmary, Barts Health NHS Trust, Belfast City Hospital, Royal United Hospitals Bath, The Royal Marsden Hospital (LONDON)

PPPIMS: Preoperative Planning with PSMA-PET in Melanoma Surgery

This is an observational trial. During an observational trial, the standard of care treatment won’t be changed (i.e. the planned surgery or drug treatment), but doctors may want to just take some extra tests or scans to see how they can improve the care of patients.As standard, before surgery to remove melanoma can take place, scans are performed to take images of the inside of the body to be able to see where there [...]

Locations: The Royal Marsden Hospital (LONDON)

REACT: REmission induction of Arthritis caused by Cancer ImmunoTherapy

Inflammatory arthritis is a condition which causes swelling and pain in the joints (for example, fingers, toes, knees, hips, wrists, elbows).A side effect of immune checkpoint inhibitor (ICI) treatment can be inflammatory arthritis and this can cause symptoms that ultimately affect a patient’s quality of life, such as joint damage. Symptoms can last a long time, even after the ICI is stopped, which means that patients may need long-term treatment for the arthritis.This trial [...]

Locations: New Cross Hospital, Nuffield Orthopaedic Centre, Leeds Teaching Hospitals NHS Trust, Royal United Hospitals Bath, University Hospitals Coventry and Warwickshire NHS Trust, University Hospitals Plymouth NHS Trust, The Queen Alexandra Hospital, Guys and St Thomas' NHS Foundation Trust, Newcastle upon Tyne Hospitals NHS Foundation Trust, University Hospital Birmingham, Leicester General Hospital

TeLuRide-006: Safety and Efficacy of EIK1001 in Combination with Pembrolizumab versus Placebo and Pembrolizumab as First-Line Therapy in Patients with Advanced Melanoma

This trial aims to investigate if the combination treatment of EIK1001 with standard of care pembrolizumab is more effective at treating advanced melanoma than with pembrolizumab alone. The researchers also want to find out what the best dose of EIK1001 is, so patients may be given one of two different doses.The trial will also look at how well patients cope with the different doses of EIK1001 and the combination treatment, for example, if they [...]

Locations: Belfast City Hospital, University Hospital Southampton, Guys and St Thomas' NHS Foundation Trust, Sarah Cannon Research Institute

SUPRAME: Study of IMA203 Versus Investigator’s Choice of Treatment in Participants with Previously Treated Advanced Melanoma.

This trial aims to investigate if an experimental treatment called IMA203 is more effective than standard treatment for patients with advanced melanoma who have progressed after first line treatment with immunotherapy. The trial also aims to look at how safe this treatment is and how well patients tolerate it, including whether they experience any side effects. This research uses a new experimental treatment IMA203 (anzutresgene autoleucel or anzu-cel). An earlier study showed that [...]

Locations: University Hospital Southampton NHS Foundation Trust, The Beatson West of Scotland Cancer Centre, The Christie NHS Foundation Trust, THE ROYAL MARSDEN HOSPITAL (LONDON), THE ROYAL MARSDEN HOSPITAL (SURREY), Addenbrookes Hospital, Oxford University Hospitals NHS Foundation Trust, GUY'S HOSPITAL

TILVANCE-301: Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

For unresectable or metastatic melanoma patients currently receive standard of care treatment with immunotherapy.This trial aims to investigate if an experimental treatment called lifileucel a tumour-infiltrating lymphocyte therapy (TIL therapy) together with pembrolizumab immunotherapy can be effective as a first line treatment for patients with advanced (unresectable or metastatic) melanoma.The trial also aims to look at how safe this combination treatment is, for example, if the patient experiences any side effects.Lifileucel (TIL therapy) is [...]

Locations: University Hospital Birmingham, Freeman Hospital, Guys and St Thomas' NHS Foundation Trust, Sarah Cannon Research Institute, The Beatson West of Scotland Cancer Centre, The Royal Marsden Hospital (LONDON)

TEBE-AM: Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma

Currently, if a patient with advanced melanoma has disease progression during or after they receive treatment with immunotherapy, there aren’t many more available standard treatment options that are proven to be very effective. If the patient has a BRAF positive mutation, they can then be treated with targeted therapy, and if they have disease progression after this, they are left with few treatment options.This trial aims to investigate how effective treatment with tebentafusp or [...]

Locations: Guys and St Thomas' NHS Foundation Trust, Sarah Cannon Research Institute, The Beatson West of Scotland Cancer Centre, St Bartholomew's Hospital, The Clatterbridge Cancer Centre NHS Foundation Trust, The Christie NHS Foundation Trust, St James' University Hospital, The Royal Marsden Hospital (London), The Royal Marsden Hospital (Surrey), Addenbrookes Hospital, Queen Elizabeth Hospital Birmingham, Mount Vernon Hospital

OOB: The Liverpool Ocular Oncology Biobank

The Liverpool Ocular Oncology Biobank (OOB) works closely with local and regional hospitals in the UK to collect and store ocular biosamples, blood and associated clinical data from consenting patients for use in research relating to eye cancers and other eye diseases. Biosamples are small parts of tissue that are removed from the ocular tumour so that doctors or researchers can analyse them.The biobank aims to build a valuable collection that will be used [...]

Locations: The Liverpool Ocular Oncology Centre

MYMELANOMA: The MyMelanoma Research Study

The MyMelanoma project aims to build the world’s biggest melanoma database which will support research into melanoma all over the world.There are currently many researchers all over the world working to make things better for melanoma patients, however they are mostly working on small studies. In order to make faster progress these researchers need more information, both more detailed and from a greater number of people, and MyMelanoma will provide that data.The MyMelanoma project [...]

Locations: This is an online study; anyone in the UK can take part.